\nPhase III FDA combinational drug+biologic product. Cook MyoSite: AMDC treatment of female SUI
\nPhase II FDA Orphan drug designation 505b2 drug. Lipella Pharmaceuticals, Inc: LP-10 treatment of hemorrhagic cystitis
Samantha Pulliam will speak about steps required for Renovia Inc to receiving FDA 510(k) clearance for the next-generation leva® Pelvic Digital Therapeutic for the strengthening of pelvic floor muscles and the treatment of stress, mixed and mild to moderate urgency urinary incontinence (UI) in women.\n
Mary Gardner will present her experience in founding DelNova, Inc, a preclinical stage biotechnology company focused on treatment of urinary retention associated with intradetrusor botulinum toxin injection.\n
Part II - Panel Discussion and Audience Q+A:
\nMichael Chancellor will facilitate conversation among the panel and full audience participation. An open dialogue among all participants in this 2020 ICS Round Table will share experience and lessons learned for future physician entrepreneurs.